Bruker Corporation develops cutting-edge scientific instrumentation across multiple technology platforms serving diverse life science, pharmaceutical, and materials markets. Its historic revenue growth, driven by innovation and strategic acquisitions, resulted in record backlog entering 2026. However, 2025 saw a sharp contraction in operating income and a net loss amid rising costs, tariffs, and supply chain constraints. Heavy investment in R&D supports long-term competitive advantage but margins remain susceptible to inflationary pressures, trade uncertainties, and integration risks. The firm’s capital allocation maintains modest buybacks alongside disciplined capex to sustain technology leadership.